Economic Evaluation and HTA (CEIS-EEHTA) - Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.
Department of Accounting, Finance and Informatics, Institute for Leadership and Management in Health - Kingston University London, London, United Kingdom.
Head Neck. 2019 Apr;41(4):908-914. doi: 10.1002/hed.25481. Epub 2019 Jan 24.
In recurrent and/or metastatic head and neck squamous cell cancer, Cetuximab is administered once a week, followed by weekly doses. We present the clinical rationale of a different schedule of maintenance Cetuximab and we estimate the potential economic benefits on the health care budget from a societal perspective in Italy.
A budget impact (BI) excel-based model was developed comparing a base case scenario of 100% weekly administration with a dose of 250 mg/m to an every-other-week (EOW) administration at 50% or 100% with a dose of 500 mg/m .
In the EOW, 50% scenario it was calculated a cost reduction of €347 000 of which 70% attributable to indirect costs, increasing to €694 000 after 4 months.
In our analysis, we showed that this simplified schedule could also reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).
在复发性和/或转移性头颈部鳞状细胞癌中，西妥昔单抗每周给药一次，随后每周给药。我们提出了维持西妥昔单抗不同方案的临床原理，并从意大利社会角度估计了对医疗保健预算的潜在经济效益。
使用基于 Excel 的预算影响 (BI) 模型，我们将每周 100%给药方案（剂量为 250mg/m）与每两周（EOW）50%或 100%给药方案（剂量为 500mg/m）进行比较。
在 EOW，50%的情况下，我们计算出成本降低了 347000 欧元，其中 70%归因于间接成本，4 个月后增加到 694000 欧元。
在我们的分析中，我们表明这种简化的方案还可以降低医疗系统（直接成本）和社会（间接成本）的治疗成本。
